Spherical Manifolds Capture Drug-Induced Changes in Tumor Cell Cycle Behavior

Olivia Wen1, Samuel C Wolff2, Wayne Stallaert3

  • 1Department of Biology, University of North Carolina at Chapel Hill, NC, United States.

Insights

CDK4/6 inhibitors show promise in ER+/HER2- breast cancer, but resistance is common. New computational methods reveal cell cycle shifts and potential resistance mechanisms, aiding precision medicine development.

Area of Science:

  • Oncology
  • Computational Biology
  • Cell Biology

Background:

  • CDK4/6 inhibitors like palbociclib are effective against ER+/HER2- breast cancer.
  • Tumor cell heterogeneity contributes to primary and acquired resistance to these therapies.
  • Understanding resistance mechanisms is crucial for developing more effective treatments.

Purpose of the Study:

  • To investigate cell cycle protein profiles in ER+ breast cancer cells under palbociclib treatment.
  • To identify mechanisms of resistance to CDK4/6 inhibitors using advanced computational analysis.
  • To explore the utility of spherical principal component analysis (SPCA) for interpreting high-dimensional biological data.

Main Methods:

  • Multiplex single-cell imaging was employed to profile cell cycle proteins.
  • Increasing concentrations of palbociclib were used to induce varying levels of drug response.
  • Spherical principal component analysis (SPCA) was applied to analyze high-dimensional cell cycle data.

Main Results:

  • SPCA visualized shifts in cell cycle states and population heterogeneity.
  • The analysis confirmed expected reductions in proliferation markers (Ki67, pRB).
  • Potential resistance mechanisms, including increased cyclin D1 and CDK2 expression, were identified.

Conclusions:

  • SPCA is a valuable tool for analyzing cell cycle dynamics and identifying resistance mechanisms in cancer.
  • Understanding these resistance pathways can inform the development of novel therapeutic strategies.
  • SPCA holds potential as a precision medicine tool for tailoring cancer treatments.